Trupanion, Inc. (NASDAQ:TRUP) COO John R. Gallagher Sells 3,100 Shares

Trupanion, Inc. (NASDAQ:TRUP - Get Free Report) COO John R. Gallagher sold 3,100 shares of the company's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $32.99, for a total value of $102,269.00. Following the sale, the chief operating officer now owns 25,549 shares of the company's stock, valued at approximately $842,861.51. This trade represents a 10.82 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Trupanion Price Performance

Shares of Trupanion stock traded up $0.74 during midday trading on Tuesday, reaching $33.20. The company had a trading volume of 586,401 shares, compared to its average volume of 641,189. The company has a current ratio of 1.71, a quick ratio of 1.66 and a debt-to-equity ratio of 0.39. The stock has a fifty day simple moving average of $43.80 and a 200 day simple moving average of $47.42. Trupanion, Inc. has a 1-year low of $19.69 and a 1-year high of $57.90. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -144.35, a price-to-earnings-growth ratio of 6.02 and a beta of 1.70.

Trupanion (NASDAQ:TRUP - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The financial services provider reported $0.04 earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by ($0.02). Trupanion had a negative return on equity of 3.08% and a negative net margin of 0.75%. The business had revenue of $337.31 million for the quarter, compared to the consensus estimate of $335.41 million. As a group, equities research analysts forecast that Trupanion, Inc. will post 0.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TRUP. Piper Sandler decreased their target price on Trupanion from $57.00 to $52.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Stifel Nicolaus reduced their price objective on Trupanion from $44.00 to $41.00 and set a "hold" rating for the company in a research report on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Trupanion presently has a consensus rating of "Moderate Buy" and an average target price of $46.60.

Remove Ads

Institutional Trading of Trupanion

A number of large investors have recently made changes to their positions in the company. SBI Securities Co. Ltd. acquired a new stake in shares of Trupanion in the fourth quarter valued at approximately $25,000. Jones Financial Companies Lllp lifted its holdings in Trupanion by 71.7% during the 4th quarter. Jones Financial Companies Lllp now owns 570 shares of the financial services provider's stock valued at $27,000 after purchasing an additional 238 shares during the last quarter. Quarry LP bought a new position in Trupanion during the fourth quarter worth $39,000. Quest Partners LLC acquired a new position in shares of Trupanion in the third quarter valued at $37,000. Finally, Aster Capital Management DIFC Ltd raised its position in shares of Trupanion by 988.5% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 1,132 shares of the financial services provider's stock valued at $55,000 after purchasing an additional 1,028 shares during the period.

About Trupanion

Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.